James J. Dignam to Survival Rate
This is a "connection" page, showing publications James J. Dignam has written about Survival Rate.
Connection Strength
0.394
-
Re: Racial disparities in cancer survival among randomized clinical trials of the Southwest Oncology Group. J Natl Cancer Inst. 2010 Feb 24; 102(4):279-80; author reply 280-2.
Score: 0.067
-
Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst. 2003 Sep 17; 95(18):1370-5.
Score: 0.043
-
Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women. J Natl Cancer Inst Monogr. 2001; (30):36-43.
Score: 0.036
-
Differences in breast cancer prognosis among African-American and Caucasian women. CA Cancer J Clin. 2000 Jan-Feb; 50(1):50-64.
Score: 0.034
-
Prognosis among African-American women and white women with lymph node negative breast carcinoma: findings from two randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). Cancer. 1997 Jul 01; 80(1):80-90.
Score: 0.028
-
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med. 2017 02 02; 376(5):417-428.
Score: 0.027
-
Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma. J Thorac Oncol. 2013 Apr; 8(4):478-86.
Score: 0.021
-
Optimization of response classification criteria for patients with malignant pleural mesothelioma. J Thorac Oncol. 2012 Nov; 7(11):1728-34.
Score: 0.020
-
A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol. 2012 Jul; 14(7):910-8.
Score: 0.020
-
Race and the prognostic influence of p53 in women with breast cancer. Ann Surg Oncol. 2012 Jul; 19(7):2334-44.
Score: 0.020
-
Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). J Clin Oncol. 2011 Apr 01; 29(10):1326-34.
Score: 0.018
-
p53 as a marker of prognosis in African-American women with breast cancer. Ann Surg Oncol. 2010 May; 17(5):1398-405.
Score: 0.017
-
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004 Sep 4-10; 364(9437):858-68.
Score: 0.012
-
Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr. 2001; (30):62-6.
Score: 0.009
-
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999 Jun 12; 353(9169):1993-2000.
Score: 0.008
-
Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998 Feb; 16(2):441-52.
Score: 0.007
-
Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996 Jul; 14(7):1982-92.
Score: 0.007